Effects of Cilostazol on the Drug-Eluting Stent in Native Coronary Arteries

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Native coronary artery disease undergoing sirolimus-eluting stent implantation (n=240). Intervention: Cilostazol vs. Clopidogrel 75 mg daily. Primary outcome: Minimal luminal diameter (MLD) at 6-month follow-up (p=0.970).

Seong-Man Kim; Doo‐Il Kim; Hwan-Jin Cho; Sang‐Hoon Seol; Dae-Kyeong Kim; Tae‐Hyun Yang; Dong-Soo Kim

doi:10.4070/kcj.2007.37.7.304

January 1, 2007Sunhwan'giOpen Access

Effects of Cilostazol on the Drug-Eluting Stent in Native Coronary Arteries

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does cilostazol improve minimal luminal diameter compared to clopidogrel in patients with successful sirolimus-eluting stent implantation?

Study Design

Type

RCT (n=240)

Blinding

Double-blind

Randomization

Computer-generated randomization lists

Multicenter

No

Structured PICO

Does cilostazol improve minimal luminal diameter compared to clopidogrel in patients with successful sirolimus-eluting stent implantation?

P

Population

240 adults with myocardial ischemia and de novo native coronary artery lesions who underwent successful sirolimus-eluting stent implantation, followed for 6 months.

I

Intervention

Cilostazol 100 mg oral twice daily plus aspirin 100 mg daily, started after 1 month of triple therapy (aspirin, clopidogrel, cilostazol) and continued until 6-month follow-up.

C

Comparator

Clopidogrel 75 mg oral daily plus aspirin 100 mg daily, started after 1 month of triple therapy (aspirin, clopidogrel, cilostazol) and continued until 6-month follow-up.

O

Outcome

Minimal luminal diameter (MLD) of the first lesion stented per patient, assessed by quantitative coronary angiography at 6 months follow-up.surrogate

Main Result

Absolute Event Rate: 2.76% vs 2.76%

p-value: p=0.970

Cilostazol was not inferior to clopidogrel for clinical anticoagulation and resulted in shorter, more focal in-stent restenosis lesions after sirolimus-eluting stent implantation, though it did not significantly improve minimal luminal diameter.

Limitations

Single-center study design
Small sample size given the low incidence rate of stent restenosis
Target lesion revascularization was based on visual analysis rather than quantitative coronary angiography
Lack of intravascular ultrasound to strictly evaluate intimal hyperplasia
Exclusion of patients at high risk of bleeding or with complex lesions/acute myocardial infarction
single center
small sample size
low incidence rate of stent restenosis
visual estimation for target lesion revascularization
lack of intravascular ultrasound to evaluate intimal hyperplasia
exclusion of high-risk patients with thrombus-associated lesions

Implication

Cilostazol is noninferior to clopidogrel for minimal luminal diameter after sirolimus-eluting stents; extends evidence on shorter, focal restenosis patterns.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2007) conducted an RCT in Native coronary artery disease undergoing sirolimus-eluting stent implantation (n=240). Cilostazol vs. Clopidogrel 75 mg daily was evaluated on Minimal luminal diameter (MLD) at 6-month follow-up (p=0.970).

synapsesocial.com/papers/6a943def0533089f4392e6f0 https://doi.org/10.4070/kcj.2007.37.7.304

View Full Paper

Ask AI

Bookmark

Share

Effects of Cilostazol on the Drug-Eluting Stent in Native Coronary Arteries

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Effects of Cilostazol on the Drug-Eluting Stent in Native Coronary Arteries

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Sunhwan'gi

Keep reading

More related papers

More from Sunhwan'gi